Hepatera: Eligibility to PRIME Scheme Granted to Myrcludex B by the European Medicines Agency

Thursday, May 25, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

MOSCOW, May 25, 2017 /PRNewswire/ --

MYR GmbH and its development partner Hepatera LLC today announced that the European

Medicines Agency (EMA) granted "PRIME eligibility" for Myrcudex B, a first in class entry inhibitor for Hepatitis Delta (D) virus.

     (Logo: http://photos.prnewswire.com/prnh/20140213/668442-b )

"It is very encouraging that the

European regulator recognizes the importance of the unmet medical problem in hepatitis delta and is willing to support the development of Myrcludex B," said Heiner Wedemeyer, MD, Professor at Hannover Medical School and Chairman of MYR's Clinical Advisory Board. "The affected patients are in urgent need of new medications and we are looking forward to the upcoming results of the Phase 2b program with this innovative drug."

"The combined efforts of academic research, public funding and small biotech development and venture activities allowed the clinical development of a completely new drug with a novel mode of action on both Hepatitis B and D virus. The enhanced dialog with EMA will now strongly facilitate further joint effort to bring Myrcludex B to the HDV/HBV co-infected patients in need as fast as possible," commented Stephan Urban, PhD, DZIF-Professor for Translational Virology at the University of Heidelberg, inventor of the technology and collaboration partner of MYR GmbH and Hepatera LLC.

About PRIME 

PRIME is a scheme launched by the European Medicines Agency (EMA) to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier.

About Myrcludex B 

Myrcludex B is a first in class entry inhibitor for treatment of chronic hepatitis B and D. The drug has shown promising efficacy in Phase 2a trials. Recruitment for Phase 2b program in HDV is completed.

About Hepatera 

Hepatera is Maxwell Biotech Venture Fund's Portfolio Company. The main activity of the company is the development of safe and effective drugs for the treatment of liver diseases for the Russian market.

About MYR GmbH 

MYR GmbH is a clinical stage biotechnology company focused on drugs for the treatment of chronic hepatitis B and D virus infections. The company was founded in 2010 and is based in Burgwedel, Germany.

About Maxwell Biotech Venture Fund 

Maxwell Biotech Venture Fund (MBVF) is the first Russian venture fund fully dedicated to investments in the life sciences sector. The fund has been created with the participation of the Russian Venture Company (RVC). MBVF portfolio companies have nine innovative clinical stage drug candidates in development.

SOURCE Hepatera

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store